knowledge -WSS

knowledge

author：focus 2025-09-30 12:10:49 - browse：28572

The back of three medicine containers, a bottle in between two boxes, all showing labels — coverage from STAT — Adobe

After a drug enters the market, it’s up to Food and Drug Administration regulators to ensure its continued safety and efficacy. A recent New York Times story suggests that, in the case of the popular asthma drug Singulair, the FDA fell short — both because the agency delayed action for years on reports from patient advocates and independent groups that the drug could cause suicidal thoughts, and because when it did add a warning label about its potential side effects in 2020, clinicians and patients still weren’t always aware of the risks.

Experts say that the Singulair incident highlights a flawed system, both in the U.S. and globally, for monitoring adverse reactions after a drug is on the market — one that will require extensive changes to address.

“The question is, how safe do you want to be?” said Ameet Sarpatwari, the assistant director of the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital. Ideally, he said, the FDA should be able to both stay on top of safety concerns and avoid unnecessarily restricting access to drugs. “Are we at the right balance? I think there are definitely situations for many drugs where you can say, no, we’re not really at the right balance, and the FDA should be taking a more aggressive stance in promoting patient safety.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Orchard's therapy for neuron disease in children wins FDA approval

WSS

Novo acquires Inversago for up to $1 billion

U.K. researchers warn about biases in medical devices, algorithms

U.K. researchers warn about biases in medical devices, algorithms

Target recalls 2.2 million additional candles due to laceration, burn hazards

CVS Caremark has created a new ploy: the drug ‘rebate credit’

SCOTUS questions limit to govt efforts to fight misinformation

hotspot

knowledge

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

Listen: Your guide to Wegovy's blockbuster heart study

Dobbs anniversary: the lost opportunity of abortion as health care

Kim Kardashian sparks debate on benefits of full

Jerome Adams on the need for new antivirals for Covid

Faced with fears of OxyContin misuse, sales reps touted its safety

Guidelines to prevent youth baseball injuries need more muscle

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Wildfire smoke exposes gaps in outdoor worker protections

Some of the ways extreme heat will change life as we know it

hotspot

Nurses recount patients attacks

CDC overhauls leadership of center that led response to Covid

Baby aspirin cuts fat buildup in liver disease patients, in small study

Timeline: Special counsel's investigation into Trump's handling of classified documents

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Physicians and social media: If you see something, say something?

hotspot

hotspot

knowledge

entertainment